Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK: Epigenetic Study of CML Stem Cells
NCT03481868Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Feb 2018
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Single-arm trial, sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Epigenetic dysregulations of in vivo TKI-resisting CML cells at Month 3. Started Feb 2018; status: recruiting.
Beyond the preview
Go deeper on NCT03481868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03481868.